Strategic Wealth Partners’s Travere Therapeutics TVTX Stock Holding History

Strategic Wealth Partners’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$16.5K	Hold	290	–	–	﹤0.01%	798
2026 Q1	$8.62K	Hold	290	–	–	﹤0.01%	922
2025 Q4	$11.1K	Hold	290	–	–	﹤0.01%	861
2025 Q3	$6.93K	Hold	290	–	–	﹤0.01%	979
2025 Q2	$4.29K	Buy	+290	New	+$4.81K	﹤0.01%	919

Other funds holding TVTX

Jupiter Topco New York $245B AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Strategic Wealth Partners's TVTX Position: Q2 2026 in Review

Strategic Wealth Partners held its Travere Therapeutics (TVTX) position steady in Q2 2026 at 290 shares worth $16.5K. The position accounts for ﹤0.01% of the portfolio, ranked #798.

Strategic Wealth Partners first reported a position in TVTX in Q2 2025 and has held it in 5 quarters since. 321 funds tracked by Wall St. Rank hold TVTX as of Q2 2026.

Strategic Wealth Partners held 290 shares of Travere Therapeutics worth $16.5K as of Q2 2026.
Strategic Wealth Partners left its Travere Therapeutics share count unchanged in Q2 2026.
Travere Therapeutics made up ﹤0.01% of Strategic Wealth Partners's portfolio in Q2 2026, its #798 holding.
Strategic Wealth Partners first reported a position in Travere Therapeutics in Q2 2025 and has held it in 5 quarters since.
321 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2026.

Based on Strategic Wealth Partners's 13F filing for Q2 2026, filed 12 Aug 2026.